SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: Robert K. who wrote (4941)11/29/1997 10:50:00 PM
From: Cacaito  Respond to of 17367
 
Patients in the MeningoII study were very sick, they were all in pediatric ICUs and they were receiving vasopressors to help against the shock, so Xoma went after a very sick population by all types of measurements.

The animal data and other preliminary clinical data has proven the healing properties of BPI and the studies are more difficult in humans , due to the ethical problems and the need for placebo control.